Skip to main content

Advertisement

Log in

Abstract

Most lymphoma types are fluorodeoxyglucose positron emission tomography (FDG-PET) positive, and FDG-PET/computed tomography (CT) is used routinely in staging and treatment evaluation of lymphomas. PET/CT imaging is important for contouring of the target for radiotherapy and changes the radiation volumes significantly compared with radiotherapy planning based on CT alone. Modern advanced imaging techniques with image fusion and inspiration breath hold have enabled further refinements of radiotherapy for lymphoma, reducing the risks of long-term side effects while maintaining the high cure rate for these diseases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Illidge T, Specht L, Yahalom J, Aleman B, Berthelsen AK, Constine L, Dabaja B, Dharmarajan K, Ng A, Ricardi U, Wirth A (2014) Modern radiation therapy for nodal non Hodgkin lymphoma—target definition and dose guidelines from the International Lymphoma Radiation Oncology Group (ILROG). Int J Radiat Oncol Biol Phys 89:49–58

    Article  PubMed  Google Scholar 

  2. Specht L, Yahalom J, Illidge T, Berthelsen AK, Constine LS, Eich HT, Girinsky T, Hoppe RT, Mauch P, Mikhaeel NG, Ng A (2014) Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG). Int J Radiat Oncol Biol Phys 89:854–862

    Article  PubMed  Google Scholar 

  3. Yahalom J, Illidge T, Specht L, Hoppe RT, Li YX, Tsang R, Wirth A (2015) Modern radiation therapy for extranodal lymphomas: field and dose guidelines from the international lymphoma radiation oncology group. Int J Radiat Oncol Biol Phys 92:11–31

    Article  PubMed  Google Scholar 

  4. Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32:3059–3068

    Article  PubMed  Google Scholar 

  5. Barrington SF, Mikhaeel NG (2014) When should FDG-PET be used in the modern management of lymphoma? Br J Haematol 164(3):315–328

    Article  PubMed  Google Scholar 

  6. Gallamini A, Hutchings M, Rigacci L, Specht L, Merli F, Hansen M, Patti C, Loft A, Di RF, D’Amore F, Biggi A, Vitolo U, Stelitano C, Sancetta R, Trentin L, Luminari S, Iannitto E, Viviani S, Pierri I, Levis A (2007) Early interim 2-[18F]fluoro-2-deoxy-d-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin’s lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 25:3746–3752

    Article  CAS  PubMed  Google Scholar 

  7. Haioun C, Itti E, Rahmouni A, Brice P, Rain JD, Belhadj K, Gaulard P, Garderet L, Lepage E, Reyes F, Meignan M (2005) [18F]fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood 106:1376–1381

    Article  CAS  PubMed  Google Scholar 

  8. Hutchings M, Loft A, Hansen M, Pedersen LM, Buhl T, Jurlander J, Buus S, Keiding S, D’Amore F, Boesen AM, Berthelsen AK, Specht L (2006) FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 107:52–59

    Article  CAS  PubMed  Google Scholar 

  9. Jerusalem G, Beguin Y, Fassotte MF, Najjar F, Paulus P, Rigo P, Fillet G (2000) Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin’s lymphoma. Haematologica 85:613–618

    CAS  PubMed  Google Scholar 

  10. Kostakoglu L, Coleman M, Leonard JP, Kuji I, Zoe H, Goldsmith SJ (2002) PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin’s disease. J Nucl Med 43:1018–1027

    PubMed  Google Scholar 

  11. Mikhaeel NG, Hutchings M, Fields PA, O’Doherty MJ, Timothy AR (2005) FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol 16:1514–1523

    Article  CAS  PubMed  Google Scholar 

  12. Mylam KJ, Kostakoglu L, Hutchings M, Coleman M, Lamonica D, Czuczman MS, Diehl LF, Nielsen AL, Jensen P, Loft A, Hendel HW, Iyer V, Leppa S, Jyrkkio S, Holte H, Eriksson M, Gillstrom D, Hansen PB, Seppanen M, Hjorthaug K, Brown PD, Pedersen LM (2014) F-fluorodeoxyglucose-positron emission tomography/computed tomography after one cycle of chemotherapy in patients with diffuse large B-cell lymphoma: results of a Nordic/US intergroup study. Leuk Lymphoma 20:1–8

    Google Scholar 

  13. Rigacci L, Puccini B, Zinzani PL, Biggi A, Castagnoli A, Merli F, Balzarotti M, Stelitano C, Spina M, Vitolo U, Stefoni V, Levis A, Gotti M, Rosaria S, Maria SP, Bosi A, Gallamini A (2015) The prognostic value of positron emission tomography performed after two courses (INTERIM-PET) of standard therapy on treatment outcome in early stage Hodgkin lymphoma: a multicentric study by the fondazione italiana linfomi (FIL). Am J Hematol 90(6):499–503

    Article  CAS  PubMed  Google Scholar 

  14. Spaepen K, Stroobants S, Dupont P, Vandenberghe P, Thomas J, de Groot T, Balzarini J, De Wolf-Peeters C, Mortelmans L, Verhoef G (2002) Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin’s lymphoma. Ann Oncol 13:1356–1363

    Article  CAS  PubMed  Google Scholar 

  15. Zinzani PL, Quaglino P, Pimpinelli N, Berti E, Baliva G, Rupoli S, Martelli M, Alaibac M, Borroni G, Chimenti S, Alterini R, Alinari L, Fierro MT, Cappello N, Pileri A, Soligo D, Paulli M, Pileri S, Santucci M, Bernengo MG (2006) Prognostic factors in primary cutaneous B-cell lymphoma: the Italian Study Group for Cutaneous Lymphomas. J Clin Oncol 24:1376–1382

    Article  PubMed  Google Scholar 

  16. Radford J, Illidge T, Counsell N, Hancock B, Pettengell R, Johnson P, Wimperis J, Culligan D, Popova B, Smith P, McMillan A, Brownell A, Kruger A, Lister A, Hoskin P, O’Doherty M, Barrington S (2015) Results of a trial of PET-directed therapy for early-stage Hodgkin’s lymphoma. N Engl J Med 372:1598–1607

    Article  CAS  PubMed  Google Scholar 

  17. Raemaekers JM, Andre MP, Federico M, Girinsky T, Oumedaly R, Brusamolino E, Brice P, Ferme C, van der Maazen R, Gotti M, Bouabdallah R, Sebban CJ, Lievens Y, Re A, Stamatoullas A, Morschhauser F, Lugtenburg PJ, Abruzzese E, Olivier P, Casasnovas RO, van IG, Raveloarivahy T, Bellei M, van der Borght T, Bardet S, Versari A, Hutchings M, Meignan M, Fortpied C (2014) Omitting radiotherapy in early positron emission tomography-negative stage i/ii hodgkin lymphoma is associated with an increased risk of early relapse: clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol 32:1188–1194

    Article  PubMed  Google Scholar 

  18. Savage KJ, Connors JM, Klasa RJ, Hoskins P, Shenkier TN, Gascoyne RD, Bhimji S, Pickles T, Benard F, Wilson D, Sehn LH (2011) The use of FDG-PET to guide consolidative radiotherapy in patients with advanced-stage Hodgkin lymphoma with residual abnormalities on CT scan following ABVD chemotherapy. J Clin Oncol 29(Suppl) (abstr 8034)

  19. Engert A, Haverkamp H, Kobe C, Markova J, Renner C, Ho A, Zijlstra J, Král Z, Fuchs M, Hallek M, Kanz L, Döhner H, Dörken B, Engel N, Topp M, Klutmann S, Amthauer H, Bockisch A, Kluge R, Kratochwil C, Schober O, Greil R, Andreesen R, Kneba M, Pfreundschuh M, Stein H, Eich HT, Müller RP, Dietlein M, Borchmann P, Diehl V (2012) Reduced intensity of chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin lymphoma: an open-label, randomised phase 3 trial. Lancet 379:1791–1799

    Article  CAS  PubMed  Google Scholar 

  20. Kobe C, Kuhnert G, Kahraman D, Haverkamp H, Eich HT, Franke M, Persigehl T, Klutmann S, Amthauer H, Bockisch A, Kluge R, Wolf HH, Maintz D, Fuchs M, Borchmann P, Diehl V, Drzezga A, Engert A, Dietlein M (2014) Assessment of tumor size reduction improves outcome prediction of positron emission tomography/computed tomography after chemotherapy in advanced-stage hodgkin lymphoma. J Clin Oncol 32:1776–1781

    Article  PubMed  Google Scholar 

  21. Kriz J, Reinartz G, Dietlein M, Kobe C, Kuhnert G, Haverkamp H, Haverkamp U, Engenhart-Cabillic R, Herfarth K, Lukas P, Schmidberger H, Staar S, Hegerfeld K, Baues C, Engert A, Eich HT (2015) Relapse analysis of irradiated patients within the hd15 trial of the german hodgkin study group. Int J Radiat Oncol Biol Phys 92(1):46–53

    Article  PubMed  Google Scholar 

  22. Sehn LH, Klasa R, Shenkier T, Villa D, Slack GW, Gascoyne RD, Benard F, Wilson D, Morris J, Parsons C, Pickles T, Connors JM, Savage KG (2013) Long-term experience with PET-guided consolidative radiation therapy (XRT) in patients with advanced stage diffuse large b cell lymphoma (DLBCL) treated with R-CHOP. Hematol Oncol 31(S1):137 (abstract 123)

    Google Scholar 

  23. Girinsky T, Ghalibafian M, Bonniaud G, Bayla A, Magne N, Ferreira I, Lumbroso J (2007) Is FDG-PET scan in patients with early stage Hodgkin lymphoma of any value in the implementation of the involved-node radiotherapy concept and dose painting? Radiother Oncol 85:178–186

    Article  PubMed  Google Scholar 

  24. Girinsky T, Specht L, Ghalibafian M, Edeline V, Bonniaud G, Van Der MR, Aleman B, Paumier A, Meijnders P, Lievens Y, Noordijk E, Poortmans P (2008) The conundrum of Hodgkin lymphoma nodes: to be or not to be included in the involved node radiation fields. The EORTC-GELA lymphoma group guidelines. Radiother Oncol 88:202–210

    Article  PubMed  Google Scholar 

  25. Bonadonna G, Bonfante V, Viviani S, Di Russo A, Villani F, Valagussa P (2004) ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin’s disease: long-term results. J Clin Oncol 22(14):2835–2841

    Article  PubMed  Google Scholar 

  26. Engert A, Schiller P, Josting A, Herrmann R, Koch P, Sieber M, Boissevain F, de Wit M, Mezger J, Duhmke E, Willich N, Muller RP, Schmidt BF, Renner H, Muller-Hermelink HK, Pfistner B, Wolf J, Hasenclever D, Loffler M, Diehl V (2003) Involved-Field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable hodgkin’s lymphoma: results of the HD8 trial of the german hodgkin’s lymphoma study group. J Clin Oncol 21(19):3601–3608

    Article  PubMed  Google Scholar 

  27. Ferme C, Eghbali H, Meerwaldt JH, Rieux C, Bosq J, Berger F, Girinsky T, Brice P, van’t Veer MB, Walewski JA, Lederlin P, Tirelli U, Carde P, Van Den Neste E, Gyan E, Monconduit M, Divine M, Raemaekers JMM, Salles G, Noordijk EM, Creemers GJ, Gabarre J, Hagenbeek A, Reman O, Blanc M, Thomas J, Vie B, Kluin-Nelemans JC, Viseu F, Baars JV, Poortmans P, Lugtenburg PJ, Carrie C, Jaubert J, Henry-Amar M, The EORTC-GELA H8 Trial (2007) Chemotherapy plus involved-field radiation in early-stage hodgkin’s disease. N Engl J Med 357(19):1916–1927

    Article  CAS  PubMed  Google Scholar 

  28. Girinsky T, Van Der MR, Specht L, Aleman B, Poortmans P, Lievens Y, Meijnders P, Ghalibafian M, Meerwaldt J, Noordijk E (2006) Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. Radiother Oncol 79:270–277

    Article  PubMed  Google Scholar 

  29. de Bruin ML, Sparidans J, van’t Veer MB, Noordijk EM, Louwman MW, Zijlstra JM, van den Berg H, Russell NS, Broeks A, Baaijens MH, Aleman BM, van Leeuwen FE (2009) Breast cancer risk in female survivors of Hodgkin’s lymphoma: lower risk after smaller radiation volumes. J Clin Oncol 27:4239–4246

    Article  PubMed  Google Scholar 

  30. Maraldo MV, Brodin NP, Vogelius IR, Aznar MC, Munck Af RP, Petersen PM, Specht L (2012) Risk of developing cardiovascular disease after involved node radiotherapy versus mantle field for Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 83:1232–1237

    Article  PubMed  Google Scholar 

  31. Maraldo MV, Brodin P, Aznar MC, Vogelius IR, Munck Af RP, Petersen PM, Specht L (2013) Doses to carotid arteries after modern radiation therapy for Hodgkin lymphoma: is stroke still a late effect of treatment? Int J Radiat Oncol Biol Phys 87:297–303

    Article  PubMed  Google Scholar 

  32. Maraldo MV, Brodin NP, Aznar MC, Vogelius IR, Munck Af RP, Petersen PM, Specht L (2013) Estimated risk of cardiovascular disease and secondary cancers with modern highly conformal radiotherapy for early-stage mediastinal Hodgkin lymphoma. Ann Oncol 24:2113–2118

    Article  CAS  PubMed  Google Scholar 

  33. Berthelsen AK, Dobbs J, Kjellen E, Landberg T, Moller TR, Nilsson P, Specht L, Wambersie A (2007) What’s new in target volume definition for radiologists in ICRU Report 71? How can the ICRU volume definitions be integrated in clinical practice? Cancer Imaging 7:104–116

    Article  PubMed Central  PubMed  Google Scholar 

  34. Filippi AR, Ciammella P, Piva C et al (2014) Involved-site image-guided intensity modulated versus 3D conformal radiation therapy in early stage supradiaphragmatic Hodgkin lymphoma. Int J Radiation Oncol Biol Phys 89(2):370–375

    Article  Google Scholar 

  35. Brianzoni E, Rossi G, Ancidei S, Berbellini A, Capoccetti F, Cidda C, D’Avenia P, Fattori S, Montini GC, Valentini G, Proietti A, Algranati C (2005) Radiotherapy planning: pET/CT scanner performances in the definition of gross tumour volume and clinical target volume. Eur J Nucl Med Mol Imaging 32:1392–1399

    Article  PubMed  Google Scholar 

  36. Dizendorf EV, Baumert BG, von Schulthess GK, Lutolf UM, Steinert HC (2003) Impact of whole-body 18F-FDG PET on staging and managing patients for radiation therapy. J Nucl Med 44:24–29

    PubMed  Google Scholar 

  37. Hutchings M, Loft A, Hansen M, Berthelsen AK, Specht L (2007) Clinical impact of FDG-PET/CT in the planning of radiotherapy for early-stage Hodgkin lymphoma. Eur J Haematol 78:206–212

    Article  PubMed  Google Scholar 

  38. Lee YK, Cook G, Flower MA, Rowbottom C, Shahidi M, Sharma B, Webb S (2004) Addition of 18F-FDG-PET scans to radiotherapy planning of thoracic lymphoma. Radiother Oncol 73:277–283

    Article  PubMed  Google Scholar 

  39. Terezakis SA, Hunt MA, Kowalski A, McCann P, Schmidtlein CR, Reiner A, Gonen M, Kirov AS, Gonzales AM, Schoder H, Yahalom J (2011) [(1)(8)F]FDG-positron emission tomography coregistration with computed tomography scans for radiation treatment planning of lymphoma and hematologic malignancies. Int J Radiat Oncol Biol Phys 81:615–622

    Article  PubMed  Google Scholar 

  40. Girinsky T, Auperin A, Ribrag V, Elleuch M, Ferme C, Bonniaud G, Ruelle C, Alberini JL, Celebic A, Edeline V (2014) Role of FDG-PET in the implementation of involved-node radiation therapy for Hodgkin lymphoma patients. Int J Radiat Oncol Biol Phys 89:1047–1052

    Article  PubMed  Google Scholar 

  41. Metwally H, Courbon F, David I, Filleron T, Blouet A, Rives M, Izar F, Zerdoud S, Plat G, Vial J, Robert A, Laprie A (2011) Coregistration of prechemotherapy PET-CT for planning pediatric Hodgkin’s disease radiotherapy significantly diminishes interobserver variability of clinical target volume definition. Int J Radiat Oncol Biol Phys 80:793–799

    Article  PubMed  Google Scholar 

  42. Robertson VL, Anderson CS, Keller FG, Halkar R, Goodman M, Marcus RB, Esiashvili N (2011) Role of FDG-PET in the definition of involved-field radiation therapy and management for pediatric Hodgkin’s lymphoma. Int J Radiat Oncol Biol Phys 80:324–332

    Article  PubMed  Google Scholar 

  43. Terezakis SA, Schoder H, Kowalski A, McCann P, Lim R, Turlakov A, Gonen M, Barker C, Goenka A, Lovie S, Yahalom J (2014) A prospective study of (1)(8)FDG-PET with CT coregistration for radiation treatment planning of lymphomas and other hematologic malignancies. Int J Radiat Oncol Biol Phys 89:376–383

    Article  PubMed  Google Scholar 

  44. Gregoire V (2004) Is there any future in radiotherapy planning without the use of PET: unraveling the myth. Radiother Oncol 73:261–263

    Article  PubMed  Google Scholar 

  45. Jarritt PH, Carson KJ, Hounsell AR, Visvikis D (2006) The role of PET/CT scanning in radiotherapy planning. Br J Radiol 79(1):S27–S35

    Article  PubMed  Google Scholar 

  46. Berthelsen AK, Holm S, Loft A, Klausen TL, Andersen F, Hojgaard L (2005) PET/CT with intravenous contrast can be used for PET attenuation correction in cancer patients. Eur J Nucl Med Mol Imaging 32:1167–1175

    Article  CAS  PubMed  Google Scholar 

  47. Aznar MC, Maraldo MV, Schut DA, Lundemann M, Brodin NP, Vogelius IR, Berthelsen AK, Specht L, Petersen PM (2015) Minimizing late effects for patients with mediastinal hodgkin lymphoma: deep Inspiration Breath-Hold, IMRT, or Both? Int J Radiat Oncol Biol Phys 92:169–174

    Article  PubMed  Google Scholar 

  48. Paumier A, Ghalibafian M, Beaudre A, Ferreira I, Pichenot C, Messai T, Lessard NA, Lefkopoulos D, Girinsky T (2011) Involved-node radiotherapy and modern radiation treatment techniques in patients with Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 80:199–205

    Article  PubMed  Google Scholar 

  49. Paumier A, Ghalibafian M, Gilmore J, Beaudre A, Blanchard P, el Nemr M, Azoury F, al Hamokles H, Lefkopoulos D, Girinsky T (2012) Dosimetric benefits of intensity-modulated radiotherapy combined with the deep-inspiration breath-hold technique in patients with mediastinal Hodgkin’s lymphoma. Int J Radiat Oncol Biol Phys 82:1522–1527

    Article  PubMed  Google Scholar 

  50. Petersen PM, Aznar MC, Berthelsen AK, Loft A, Schut DA, Maraldo M, Josipovic M, Klausen TL, Andersen FL, Specht L (2015) Prospective phase II trial of image-guided radiotherapy in Hodgkin lymphoma: benefit of deep inspiration breath-hold. Acta Oncol 54:60–66

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Umberto Ricardi.

Ethics declarations

Conflict of interest

The authors of this review article (Umberto Ricardi, Lena Specht, Annibale Versari, Anne Kiil Berthelsen) declare that they have no conflict of interest.

Human and animal studies

This article does not contain any studies with human or animal subjects performed by any of the authors.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ricardi, U., Specht, L., Versari, A. et al. FDG-PET and radiotherapy in lymphoma. Clin Transl Imaging 3, 321–330 (2015). https://doi.org/10.1007/s40336-015-0129-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40336-015-0129-8

Keywords

Navigation